Details of the Drug Therapeutic Target (DTT)

General Information of Drug Therapeutic Target (DTT) (ID: TTG3K2U)

DTT Name Lipoxygenase (ALOX)
Gene Name ALOX
DTT Type
Clinical trial target
 [1]
UniProt ID
NOUNIPROTAC
TTD ID
T10339

Molecular Interaction Atlas (MIA) of This DTT

Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This DTT
1 Clinical Trial Drug(s) Targeting This DTT
Drug Name Drug ID Indication ICD 11 Highest Status REF
TZI-41078 DMKJIDU Arthritis FA20 Phase 2 [1]
------------------------------------------------------------------------------------
2 Discontinued Drug(s) Targeting This DTT
Drug Name Drug ID Indication ICD 11 Highest Status REF
CPA-926 DMH5LKS Arthritis FA20 Discontinued in Phase 2 [2]
FLM-5011 DMKWTPX Inflammation 1A00-CA43.1 Discontinued in Phase 1 [3]
------------------------------------------------------------------------------------

References

1 Hydroxylamine analogs of 2,6-di-t-butylphenols: dual inhibitors of cyclooxygenase and 5-lipoxygenase or selective 5-lipoxygenase inhibitors. Bioorg Med Chem. 1995 Apr;3(4):403-10.
2 Esculetin (dihydroxycoumarin) inhibits the production of matrix metalloproteinases in cartilage explants, and oral administration of its prodrug, CPA-926, suppresses cartilage destruction in rabbit experimental osteoarthritis. J Rheumatol. 1999 Mar;26(3):654-62.
3 Lipoxygenase inhibitor FLM 5011, an effective protectant of myocardial microvessels against ischemia-reperfusion injury. Exp Toxicol Pathol. 2000 Mar;52(1):27-36.